May 30 |
Roivant Reports Financial Results for the Fourth Quarter and Fiscal Year Ended March 31, 2024, and Provides Business Update
|
May 29 |
Roivant Sciences Q4 2024 Earnings Preview
|
May 22 |
Vivek Ramaswamy Breathes New Life In Beaten Down BuzzFeed Stock: What's Going On?
|
May 16 |
Roivant to Report Financial Results for the Fourth Quarter and Fiscal Year Ended March 31, 2024, and Provide Business Update on Thursday, May 30, 2024
|
May 5 |
Institutional investors are Roivant Sciences Ltd.'s (NASDAQ:ROIV) biggest bettors and were rewarded after last week's US$290m market cap gain
|
Apr 24 |
Roivant Sciences: Cashing In On Vants And Ventures
|
Apr 2 |
Roivant announces $1.5B share buyback, positive Phase 2 data
|
Apr 2 |
Roivant Announces Positive NEPTUNE Study Results for Brepocitinib in NIU, as well as Board Authorization for up to $1.5 Billion Share Repurchase Program, Including Repurchase of Entire Sumitomo Pharma Stake for $648 Million
|